Scientists have developed an experimental nasal spray vaccine that may
protect individuals from severe acute respiratory syndrome (SARS) virus infection
if another outbreak should occur (Lancet. 2004;363:2122-2127).
Researchers from the National Institute of Allergy and Infectious Diseases,
in Bethesda, Md, designed the vaccine by creating a recombinant attenuated
parainfluenza virus that expresses the SARS envelope spike protein. (This
strain of virus is being developed as a live attenuated intranasal pediatric
vaccine against human parainfluenza virus type 3.) The spike protein is a
viral surface protein used by the SARS virus to invade human cells.
Hampton T. Promising SARS Vaccine. JAMA. 2004;292(8):916. doi:10.1001/jama.292.8.916-b
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: